Pharma BD Deal Intelligence

Novartis AG / Tourmaline Bio, Inc.

2025 · Acquisition/Merger · $1.4B · Complete

Announcement Sentiment

100

Strongly positive

Novartis agreed to acquire Tourmaline Bio for $48.00/share cash, total equity value ~$1.4B. Adds pacibekitug, a long-acting fully-human anti-IL-6 mAb with best-in-class potential for ASCVD. Completed late October 2025 with 92.94% shares tendered.

Key facts

Announced Sep 09, 2025
Closed Oct 27, 2025
Deal value $1.4B
Deal type Acquisition/Merger
Therapeutic area Atherosclerotic cardiovascular disease (ASCVD)
Indications Atherosclerotic cardiovascular disease (ASCVD)
Key assets Pacibekitug
Mechanism Long-acting anti-IL-6 monoclonal antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals